LONDON and CARLSBAD, Calif., March 13, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, today announced receipt of Notices of Allowance for five new Epidiolex® patent applications that will be listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) if the NDA for Epidiolex is approved. Once issued, these patents are set to expire in 2035. One or more patents may be eligible for additional patent term through patent term adjustment and/or regulatory exclusivities.
“The allowance of these important patent applications confirms GW’s innovative science and leadership in developing cannabinoid-based medicines and provides meaningful additional exclusivity for Epidiolex,” stated Justin Gover, GW’s Chief Executive Officer. “We have numerous additional patent
... read more at: https://globenewswire.com/news-release/2018/03/13/1421662/0/en/GW-Pharmaceuticals-Announces-Receipt-of-Notices-of-Allowance-by-the-United-States-Patent-and-Trademark-Office-USPTO-for-Five-New-Epidiolex-cannabidiol-Patents.html